To investigate whether the proposed iRGD-induced tumour-to-blood transport of AFP is indeed tumour-specific or also occurs in mice with chronic hepatic inflammation and non-tumoral AFP production, we examined the effect of iRGD on blood AFP levels in three different mouse models of liver fibrosis (Ad-2D6 virus-induced autoimmune hepatitis, Mdr2−/− mice or CCl4 treatment). The gene discussed is AFP; the disease is Hepatic fibrosis.